Duke Energy Corp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Duke Energy Corp trades at $116.77 (market cap $91.10B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.68 (market cap $2.27B). The key difference: Duke Energy Corp is far larger — about 40.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Duke Energy Corp pays a 3.71% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DUK | SLS | |
|---|---|---|
Market Cap | $91.10B | $2.27B |
Volume | 4,199,050 | 4,179,659 |
Sector | Utilities | Health |
52-Week High | $133.46 | $15.46 |
52-Week Low | $113.23 | $1.39 |
Typical Hold Time | 74 Days | — |
Enterprise Value | $183.61B | $2.14B |
Dividend Yield | 3.71% | — |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.55, up 0.91% today, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue grew to $32.24B in 2025, and net income margin improved to 15.78%. Recent news highlights dividend declarations and data center growth opportunities, though rising Treasury yields pose a headwind for utility stocks.
DUK offers a stable dividend and benefits from data center demand, but high debt levels and interest rate sensitivity present risks. Analyst consensus is a Buy with a $134.44 price target, implying 15% upside. The stock's valuation is reasonable with a P/E of 17.6, supporting a cautious bullish outlook amid macroeconomic pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →